Brokerages Anticipate Esperion Therapeutics, Inc. (NASDAQ:ESPR) Will Post Earnings of -$0.95 Per Share

Equities analysts forecast that Esperion Therapeutics, Inc. (NASDAQ:ESPR – Get Rating) will report earnings per share of ($0.95) for the current fiscal quarter, according to Zacks. Five analysts have issued estimates for Esperion Therapeutics’ earnings. The highest EPS estimate is ($0.85) and the lowest is ($1.03). Esperion Therapeutics reported earnings per share of ($3.50) during the same quarter last year, which would suggest a positive year over year growth rate of 72.9%. The company is expected to issue its next quarterly earnings report on Monday, January 1st.

According to Zacks, analysts expect that Esperion Therapeutics will report full year earnings of ($3.60) per share for the current fiscal year, with EPS estimates ranging from ($3.90) to ($3.20). For the next year, analysts expect that the firm will report earnings of ($2.06) per share, with EPS estimates ranging from ($3.15) to $0.18. Zacks’ EPS averages are an average based on a survey of sell-side research analysts that follow Esperion Therapeutics.

Esperion Therapeutics (NASDAQ:ESPR – Get Rating) last released its earnings results on Tuesday, February 22nd. The biopharmaceutical company reported ($1.77) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($2.32) by $0.55. The business had revenue of $15.40 million for the quarter, compared to analysts’ expectations of $14.48 million. The company’s revenue was up 60.4% compared to the same quarter last year. During the same period last year, the firm earned ($3.89) EPS.

A number of brokerages have recently commented on ESPR. Credit Suisse Group cut their price target on Esperion Therapeutics from $8.00 to $6.00 and set a “neutral” rating for the company in a report on Friday, January 14th. Northland Securities lowered their price target on Esperion Therapeutics from $10.00 to $5.00 in a research report on Wednesday, January 12th. HC Wainwright began coverage on Esperion Therapeutics in a research report on Thursday, March 10th. They issued a “buy” rating and a $22.00 price target on the stock. Finally, StockNews.com assumed coverage on Esperion Therapeutics in a report on Thursday, March 31st. They set a “sell” rating on the stock. Three investment analysts have rated the stock with a sell rating, three have issued a hold rating and four have given a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $27.50.

ESPR opened at $5.89 on Friday. The business has a 50 day moving average price of $4.68 and a 200 day moving average price of $6.18. Esperion Therapeutics has a twelve month low of $3.28 and a twelve month high of $28.78. The firm has a market cap of $370.01 million, a P/E ratio of -0.62 and a beta of 0.66.

Hedge funds and other institutional investors have recently made changes to their positions in the business. Kestra Advisory Services LLC bought a new stake in Esperion Therapeutics during the 4th quarter worth $164,000. Centiva Capital LP acquired a new position in Esperion Therapeutics during the 3rd quarter worth approximately $182,000. GSA Capital Partners LLP bought a new stake in Esperion Therapeutics during the 3rd quarter worth approximately $285,000. National Bank of Canada FI bought a new stake in Esperion Therapeutics during the 4th quarter worth approximately $61,000. Finally, Tudor Investment Corp Et Al increased its holdings in Esperion Therapeutics by 140.6% during the 3rd quarter. Tudor Investment Corp Et Al now owns 70,571 shares of the biopharmaceutical company’s stock worth $850,000 after purchasing an additional 41,237 shares in the last quarter.

Esperion Therapeutics Company Profile (Get Rating)

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia.

Featured Articles